A Randomized, Open-Label, Phase 3 Study of Nivolumab (BMS-936558) vs. Everolimus in Subjects with Advanced or Metastatic Clear-Cell Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic Therapy

Trial Profile

A Randomized, Open-Label, Phase 3 Study of Nivolumab (BMS-936558) vs. Everolimus in Subjects with Advanced or Metastatic Clear-Cell Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic Therapy

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 06 Nov 2017

At a glance

  • Drugs Nivolumab (Primary) ; Everolimus
  • Indications Renal cell carcinoma
  • Focus Registrational; Therapeutic Use
  • Acronyms CheckMate-025
  • Sponsors Bristol-Myers Squibb; Ono Pharmaceutical
  • Most Recent Events

    • 06 Nov 2017 Three-year overall survival data from this trial was presented at the 16th International Kidney Cancer Symposium (KCS), according to a Bristol-Myers Squibb media release.
    • 06 Nov 2017 Three-year overall survival data presented in a Bristol-Myers Squibb media release.
    • 12 Oct 2017 Results comparing survival differences between crossover non-crossover using networked data from HOPE 205, CHECKMATE-025,TARGET, AXIS, RECORD-1, METEOR studies, presented at the 20th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top